Advertisement
CLLS vs CMVLF
Which Stock Would AI Choose? Cellectis S.A. (CLLS) vs. Cellectis S.A. (CMVLF) Stock Comparison
Key Takeaways
- Both CLLS and CMVLF represent the same company, Cellectis S.A., a clinical-stage biotech focused on gene-editing for CAR-T therapies (chimeric antigen receptor T-cells).
- CLLS trades on NASDAQ with higher liquidity and visibility, while CMVLF is the OTC listing with lower trading volume.
- Recent positive interim data from the cema-cel pivotal trial in large B-cell lymphoma (LBCL) has boosted sentiment for Cellectis, highlighting strong minimal residual disease (MRD) clearance rates.
- CLLS shows YTD return of about 10.67% and 1-year return over 196%, reflecting robust momentum in recent market activity.
- High beta (2.71) indicates elevated volatility for both listings amid biotech sector swings and clinical developments.
- Traders may prefer CLLS for better market access, while OTC CMVLF offers similar exposure with potentially wider spreads.
Introduction
This comparison examines CLLS and CMVLF, dual listings of Cellectis S.A., a Paris-based clinical-stage biotechnology firm pioneering gene-editing technologies for allogeneic CAR-T therapies in immuno-oncology. Investors and traders interested in biotech innovation, particularly off-the-shelf cell therapies targeting cancers like acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma, will find this relevant. With recent clinical milestones driving sector attention, understanding the nuances between NASDAQ and OTC listings aids in evaluating liquidity, pricing dynamics, and relative performance in the current volatile market environment.
CLLS Overview and Recent Performance
CLLS, the NASDAQ American Depositary Receipt (ADR) for Cellectis S.A., operates in the healthcare biotechnology sector, developing gene-edited allogeneic CAR-T product candidates such as lasme-cel for relapsed/refractory (r/r) ALL and eti-cel for B-cell non-Hodgkin's lymphoma. The company's TALEN gene-editing platform supports a pipeline addressing immuno-oncology and other indications like renal cell carcinoma.
In recent market activity, CLLS has exhibited strong momentum, with a year-to-date return of approximately 10.67% and over 196% gain over the past year. Trading around $4.27 with a market cap near $440 million, the stock's 52-week range spans $1.33 to $5.48, underscoring volatility (beta 2.71). Sentiment has improved following interim data from the ALPHA3 pivotal trial for cema-cel, licensed to partners like Servier and Allogene, showing 58.3% MRD negativity versus 16.7% in controls, with favorable safety. Analyst reiterations, such as Market Outperform at $8 target, further support positive positioning amid broader biotech recovery.
CMVLF Overview and Recent Performance
CMVLF serves as the over-the-counter (OTC) listing for the same entity, Cellectis S.A., sharing identical business focus on gene-editing technologies for CAR-T therapies and gene therapies. Key programs mirror those of CLLS, including BALLI-01, NatHaLi-01, and TRAVERSE trials targeting hematologic malignancies and solid tumors.
Recent weeks have seen CMVLF track closely with its NASDAQ counterpart, benefiting from the same cema-cel trial highlights that demonstrated superior MRD clearance and tolerability in LBCL consolidation. Priced around $4.50 in recent quotes, with a market cap over $477 million and 52-week range of $1.25 to $5.04, it reflects similar high volatility (beta 2.71) but thinner volume. Year-to-date and longer-term returns align broadly, influenced by clinical catalysts and sector sentiment, though OTC dynamics contribute to occasional pricing divergences from CLLS.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available that trade thousands of tickers across diverse strategies, timeframes, and styles like swing trading, pattern recognition, and sector rotation. Only the most suitable for prevailing market conditions—based on AI analysis of volatility, momentum, and performance—earn a spot among the 25 featured out of 351 total bots. Notable stats include annualized returns up to +136.62%, win rates from 53% to 87%, and profit factors reaching 10.87, spanning sectors like semiconductors, energy, and aerospace. Examples: a semiconductors bot at +99.53% annualized with 68.54% win rate, and small-cap trend trader at +97.15%. Explore these for data-driven insights tailored to current conditions.
Head-to-Head Comparison
Both CLLS and CMVLF share Cellectis S.A.'s business model centered on TALEN-enabled allogeneic CAR-T, contrasting autologous therapies with off-the-shelf scalability and lower manufacturing costs. Growth drivers like the cema-cel ALPHA3 data (41.6% MRD difference) and potential milestones up to $340 million equally propel both.
Recent momentum favors CLLS due to higher liquidity on NASDAQ versus OTC's lower volume and wider spreads for CMVLF. Risk factors, including clinical trial outcomes and biotech funding environment, apply uniformly, amplified by high beta. Sector exposure remains pure-play immuno-oncology. Market sentiment leans toward CLLS for institutional access, while CMVLF suits traders tolerant of OTC trade-offs like reduced transparency.
Tickeron AI Verdict
Tickeron’s AI would currently favor CLLS over CMVLF due to superior liquidity, tighter spreads, and analyst coverage on NASDAQ, enhancing trend consistency amid recent catalysts like cema-cel data. While relative positioning is nearly identical given shared fundamentals, CLLS offers better stability for capturing upside in volatile biotech swings.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To understand the difference between Cellectis - ADR (CLLS) vs. Cellectis (CMVLF) it is enough to know the definitions of ADR
ADR - American depositary receipt (ADR) is a certificate issued by a U.S. depositary bank representing a specified number of shares (often 1 share) of a foreign company's stock. ADRs are denominated in U.S. dollars and trade on U.S. stock markets and OTC depending on the ADRs classification.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLLS’s FA Score shows that 0 FA rating(s) are green whileCMVLF’s FA Score has 1 green FA rating(s).
- CLLS’s FA Score: 0 green, 5 red.
- CMVLF’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLLS’s TA Score shows that 4 TA indicator(s) are bullish while CMVLF’s TA Score has 2 bullish TA indicator(s).
- CLLS’s TA Score: 4 bullish, 7 bearish.
- CMVLF’s TA Score: 2 bullish, 1 bearish.
Price Growth
CLLS (@Biotechnology) experienced а -2.53% price change this week, while CMVLF (@Biotechnology) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.02%. For the same industry, the average monthly price growth was +7.74%, and the average quarterly price growth was +9.80%.
Reported Earning Dates
CLLS is expected to report earnings on May 11, 2026.
Industries' Descriptions
@Biotechnology (+5.02% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| CLLS | CMVLF | CLLS / CMVLF | |
| Capitalization | 379M | 379M | 100% |
| EBITDA | -6.07M | -6.07M | 100% |
| Gain YTD | -20.455 | -30.000 | 68% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 75.3M | 75.3M | 100% |
| Total Cash | 190M | 190M | 100% |
| Total Debt | 92.8M | 92.8M | 100% |
CLLS | CMVLF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 36 Fair valued | 33 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 96 | |
PRICE GROWTH RATING 1..100 | 40 | 52 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 50 | 29 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CMVLF's Valuation (33) in the null industry is in the same range as CLLS (36) in the Biotechnology industry. This means that CMVLF’s stock grew similarly to CLLS’s over the last 12 months.
CMVLF's Profit vs Risk Rating (100) in the null industry is in the same range as CLLS (100) in the Biotechnology industry. This means that CMVLF’s stock grew similarly to CLLS’s over the last 12 months.
CMVLF's SMR Rating (96) in the null industry is in the same range as CLLS (96) in the Biotechnology industry. This means that CMVLF’s stock grew similarly to CLLS’s over the last 12 months.
CLLS's Price Growth Rating (40) in the Biotechnology industry is in the same range as CMVLF (52) in the null industry. This means that CLLS’s stock grew similarly to CMVLF’s over the last 12 months.
CLLS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CMVLF (100) in the null industry. This means that CLLS’s stock grew similarly to CMVLF’s over the last 12 months.
| CLLS | CMVLF | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 85% | N/A |
| Stochastic ODDS (%) | 4 days ago 82% | N/A |
| Momentum ODDS (%) | 4 days ago 90% | 4 days ago 50% |
| MACD ODDS (%) | 4 days ago 90% | 4 days ago 32% |
| TrendWeek ODDS (%) | 4 days ago 86% | 4 days ago 25% |
| TrendMonth ODDS (%) | 4 days ago 71% | 4 days ago 22% |
| Advances ODDS (%) | 6 days ago 78% | N/A |
| Declines ODDS (%) | 4 days ago 88% | N/A |
| BollingerBands ODDS (%) | 4 days ago 85% | N/A |
| Aroon ODDS (%) | 4 days ago 87% | 4 days ago 54% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GCINX | 15.94 | 0.16 | +1.01% |
| Green Century MSCI Intl Indx Indvl Inv | |||
| INDCX | 14.65 | 0.06 | +0.41% |
| Victory Pioneer Disciplined Growth C | |||
| PMDIX | 21.94 | 0.08 | +0.37% |
| Principal Small-MidCap Dividend Inc Inst | |||
| FSRKX | 9.63 | 0.03 | +0.31% |
| Fidelity Strategic Real Return K6 | |||
| TWHIX | 20.85 | -0.24 | -1.14% |
| American Century Heritage Inv | |||